FrancophonIA/ELRC3.0 huggingface dataset:
English: Diuretics, corticosteroids, beta2 agonists, somatropin, somatostatin analogues, rifampin, phenytoin and St. John's Wort (Hypericum perforatum)
Estonian: Diureetikumid, kortikosteroidid, beeta-2-adrenomimeetikumid, somatropiin, somatostatiini analoogid, rifampiin, fenütoiin ja naistepunaürt (Hypericum perforatum)
English: Although there is a 49% decrease in Cmax of nateglinide in dialysis patients, the systemic availability and half-life in diabetic subjects with moderate to severe renal insufficiency (creatinine clearance 15-50 ml/min) was comparable between renal subjects requiring haemodialysis and healthy subjects.
Estonian: Kuigi dialüüsravi saavatel patsientidel esineb nategliniidi Cmax vähenemine 49% võrra, oli mõõduka kuni raske neerupuudulikkusega diabeetikutel (kreatiniini kliirens 15...50 ml/min) ravimi biosaadavus ja poolväärtusaeg võrreldav hemodialüüsi vajavate ja tervete uuritavatega.
English: Starlix contains lactose
Estonian: Starlix sialdab laktoosi
English: The recommended starting dose of Starlix is 60 mg three times daily, taken before each of the three main meals.
Estonian: Starlix'i soovituslik algannus on 60 mg kolm korda päevas, enne iga põhisöögikorda.
English: The following agents may reduce the hypoglycaemic effect of nateglinide: diuretics, corticosteroids, beta2 agonists, somatropin, somatostatin analogues (e.g. lanreotide, octreotide), rifampin, phenytoin and St. John's Wort (Hypericum perforatum).
Estonian: Järgmised ained võivad langetada nategliniidi hüpoglükeemilist toimet: diureetikumid, kortikosteroidid, beeta-2-adrenomimeetikumid, somatropiin, somatostatiini analoogid (nt lanreotiid, oktreotiid), rifampiin, fenütoiin ja naistepunaürt (Hypericum perforatum).
English: You should ask for doctor advice on driving if you have frequent episodes of hypoglycaemia or if you are not aware of the first signs of hypoglycaemia.
Estonian: Sagedaste hüpoglükeemia episoodide korral või kui te ei ole teadlik hüoglükeemia esmastest tunnustest, pidage autojuhtimise osas nõu oma arstiga.
English: Your doctor may check the amount of Starlix that you are taking on a regular basis and may adjust the dose according to your needs.
Estonian: Arst võib regulaarselt kontrollida ja vastavalt vajadusele Starlix'i annuseid muuta.
English: Alcohol may disturb the control of your blood sugar so you are advised to talk to your doctor about drinking alcohol while taking Starlix.
Estonian: Alkoholi tarbimise ja Starlix'i kasutamise kohta pidage nõu oma arstiga, sest alkohol võib häirida kontrolli veresuhkru üle.
English: Nateglinide, when taken before a meal, restores early or first phase insulin secretion, which is lost in patients with type 2 diabetes, resulting in a reduction in post-meal glucose and HbA1c.
Estonian: Enne sööki manustatud nategliniid taastab varase või esimese faasi insuliini sekretsiooni, mis puudub II tüüpi diabeediga patsientidel.
English: Lactose monohydrate Cellulose, microcrystalline Povidone
Estonian: Laktoosmonohüdraat Mikrokristalliline tselluloos Povidoon
English: Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential and toxicity to fertility and post-natal development.
Estonian: Farmakoloogilise ohutuse, korduvtoksilisuse, genotoksilisuse, kartsinogeensuse, fertiilsus- ja sünnijärgse arengu toksilisuse mittekliinilised uuringud ei ole näidanud kahjulikku toimet inimesele.
English: If you have any further questions on the use of this medicine, talk to your doctor, pharmacist or nurse.
Estonian: Kui teil on lisaküsimusi selle ravimi kasutamise kohta, pidage nõu oma arsti, apteekri või meditsiiniõega.
English: Thus, no dosage adjustment is required for digoxin, warfarin or other drugs that are CYP2C9 or CYP3A4 substrates upon coadministration with Starlix.
Estonian: Seega ei ole samaaegsel manustamisel STARLIX'iga vaja kohandada digoksiini, varfariini ega teiste CYP2C9 või CYP3A4 substraatide annuseid.
English: There is no experience of an overdose of Starlix in clinical trials.
Estonian: Kliinilistest uuringutest puuduvad kogemused STARLIX'i üleannustamise kohta.
English: The maximum recommended dose is 180 mg three times daily, taken before each of the three main meals.
Estonian: Maksimaalne soovituslik annus on 180 mg kolm korda ööpäevas, enne iga põhisöögikorda.
English: Combination with metformin is associated with an increased risk of hypoglycaemia compared to monotherapy.
Estonian: Võrreldes monoteraapiaga esineb ravimi kasutamisel koos metformiiniga suurem risk hüpoglükeemia tekkeks.
English: croscarmellose sodium; magnesium stearate and silica, colloidal anhydrous.
Estonian: naatriumkroskarmelloos, magneesiumstearaat, kolloidne veevaba ränidioksiid.
English: • Rare (may affect up to 1 in 1,000 people): mild abnormalities in liver function tests, allergic
Estonian: • harv (võivad esineda kuni 1-l inimesel 1000-st): kerged kõrvalekalded maksafunktsiooni testi tulemustes, allergilised reaktsioonid (ülitundlikkusreaktsioonid) nagu lööve ja sügelus;
English: EU/1/01/174/015 12 film-coated tablets EU/1/01/174/016 24 film-coated tablets EU/1/01/174/017 30 film-coated tablets EU/1/01/174/018 60 film-coated tablets EU/1/01/174/019 84 film-coated tablets EU/1/01/174/020 120 film-coated tablets EU/1/01/174/021 360 film-coated tablets
Estonian: EU/1/01/174/015 12 õhukese polümeerikattega tabletti EU/1/01/174/016 24 õhukese polümeerikattega tabletti EU/1/01/174/017 30 õhukese polümeerikattega tabletti EU/1/01/174/018 60 õhukese polümeerikattega tabletti EU/1/01/174/019 84 õhukese polümeerikattega tabletti EU/1/01/174/020 120 õhukese polümeerikattega tabletti EU/1/01/174/021 360 õhukese polümeerikattega tabletti
English: EU/1/01/174/001 12 film-coated tablets EU/1/01/174/002 24 film-coated tablets EU/1/01/174/003 30 film-coated tablets EU/1/01/174/004 60 film-coated tablets EU/1/01/174/005 84 film-coated tablets EU/1/01/174/006 120 film-coated tablets EU/1/01/174/007 360 film-coated tablets
Estonian: EU/1/01/174/001 12 õhukese polümeerikattega tabletti EU/1/01/174/002 24 õhukese polümeerikattega tabletti EU/1/01/174/003 30 õhukese polümeerikattega tabletti EU/1/01/174/004 60 õhukese polümeerikattega tabletti EU/1/01/174/005 84 õhukese polümeerikattega tabletti EU/1/01/174/006 120 õhukese polümeerikattega tabletti EU/1/01/174/007 360 õhukese polümeerikattega tabletti
English: EU/1/01/174/008 12 film-coated tablets EU/1/01/174/009 24 film-coated tablets EU/1/01/174/010 30 film-coated tablets EU/1/01/174/011 60 film-coated tablets EU/1/01/174/012 84 film-coated tablets EU/1/01/174/013 120 film-coated tablets EU/1/01/174/014 360 film-coated tablets
Estonian: EU/1/01/174/008 12 õhukese polümeerikattega tabletti EU/1/01/174/009 24 õhukese polümeerikattega tabletti EU/1/01/174/010 30 õhukese polümeerikattega tabletti EU/1/01/174/011 60 õhukese polümeerikattega tabletti EU/1/01/174/012 84 õhukese polümeerikattega tabletti EU/1/01/174/013 120 õhukese polümeerikattega tabletti EU/1/01/174/014 360 õhukese polümeerikattega tabletti
English: Therefore, dose discontinuation is advisable in patients with severe renal impairment who present with potentiation of hypoglycaemic effect while on Starlix.
Estonian: Seetõttu on raske neerukahjustusega patsientidele soovitatav katkestada annustamine, et vältida potentseeritud hüpoglükeemilist toimet STARLIX'i kasutades.
English: Croscarmellose sodium Magnesium stearate Yellow iron oxide (E172) Hypromellose Titanium dioxide (E171) Talc
Estonian: Naatriumkroskarmelloos Magneesiumstearaat Kollane raudoksiid (E172) Hüpromelloos
English: Starlix contains lactose monohydrate.
Estonian: Starlix sisaldab laktoosmonohüdraati.
English: - if you have a severe kidney problem.
Estonian: - kui teil on raske neeruhaigus.
English: Croscarmellose sodium Magnesium stearate Red iron oxide (E172) Hypromellose Titanium dioxide (E171) Talc
Estonian: Naatriumkroskarmelloos Magneesiumstearaat Punane raudoksiid (E172) Hüpromelloos
English: Talk to your doctor, pharmacist or nurse before taking Starlix.
Estonian: Enne Starlix'i võtmist pidage nõu oma arsti, apteekri või meditsiiniõega.
English: How to store Starlix
Estonian: Kuidas Starlix'it säilitada
English: Discontinuation should be considered in patients with severe renal impairment who present with potentiation of the hypoglycaemic effect.
Estonian: Raske neerukahjustusega patsientidel, kellel potentseerub hüpoglükeemiline toime, tuleb kaaluda ravi katkestamist.
English: Excipient with known effect Lactose monohydrate: 141.5 mg per tablet.
Estonian: Teadaolevat toimet omav abiaine Tablett sisaldab 141,5 mg laktoosmonohüdraati.
English: How to take Starlix
Estonian: Kuidas Starlix'i kasutada
English: No dose adjustment is necessary in patients with mild to moderate renal impairment.
Estonian: Kerge kuni mõõduka maksakahjustusega patsientidel ei ole vaja annust kohandada.
English: Excipient with known effect Lactose monohydrate: 214 mg per tablet.
Estonian: Teadaolevat toimet omav abiaine Tablett sisaldab 214 mg laktoosmonohüdraati.
English: Do not breast-feed during treatment with Starlix.
Estonian: Starlix-ravi ajal ei tohi last imetada.
English: Each film-coated tablet contains 60 mg nateglinide.
Estonian: Iga õhukese polümeerikattega tablett sisaldab 60 mg nategliniidi (nateglinidum).
English: No dose adjustment is necessary for patients with mild to moderate hepatic impairment.
Estonian: Kerge kuni mõõduka neerukahjustusega patsientidel ei ole vaja annust kohandada.
English: Each film-coated tablet contains 180 mg nateglinide.
Estonian: Iga õhukese polümeerikattega tablett sisaldab 180 mg nategliniidi (nateglinidum).
English: Starlix 60 mg tablets nateglinide
Estonian: Starlix 60 mg tabletid nateglinidum
English: Your treatment may need to be adjusted.
Estonian: Nendel juhtudel võib osutuda vajalikuks raviskeemi kohandamine.
English: STARLIX 60 mg film-coated tablets STARLIX 120 mg film-coated tablets STARLIX 180 mg film-coated tablets
Estonian: STARLIX 60 mg õhukese polümeerikattega tabletid STARLIX 120 mg õhukese polümeerikattega tabletid STARLIX 180 mg õhukese polümeerikattega tabletid
English: Each film-coated tablet contains 120 mg nateglinide.
Estonian: Üks õhukese polümeerikattega tablett sisaldab 120 mg nategliniidi.
English: It helps to decrease blood sugar levels, especially after meals.
Estonian: Insuliin, mida organismis toodab pankreas (kõhunääre), aitab alandada veresuhkru sisaldust, eriti pärast sööki.
English: Rare: Elevations in liver enzymes.
Estonian: Harv: maksaensüümide aktiivsuse tõus.
English: Excipient with known effect Lactose monohydrate: 283 mg per tablet.
Estonian: Teadaolevat toimet omav abiaine Tablett sisaldab 283 mg laktoosmonohüdraati.
English: Starlix 180 mg tablets nateglinide
Estonian: Starlix 180 mg tabletid nateglinidum
English: Starlix 120 mg tablets nateglinide
Estonian: Starlix 120 mg tabletid nateglinidum
English: Starlix 60 mg film-coated tablets Starlix 120 mg film-coated tablets Starlix 180 mg film-coated tablets nateglinide
Estonian: Starlix 60 mg õhukese polümeerikattegatabletid Starlix 120 mg õhukese polümeerikattega tabletid Starlix 180 mg õhukese polümeerikattega tabletid nategliniid (nateglinidum)
English: Starlix 180 mg film-coated tablets are red, ovaloid tablets with “STARLIX” marked on one side and “180” on the other.
Estonian: Starlix 180 mg õhukese polümeerikattega tabletid on punast värvi, ovaalsed, tähistusega “STARLIX” ühel ja “180” teisel küljel.
English: Starlix 120 mg film-coated tablets are yellow, ovaloid tablets with “STARLIX” marked on one side and “120” on the other.
Estonian: Starlix 120 mg õhukese polümeerikattega tabletid on kollast värvi, ovaalsed, tähistusega “STARLIX” ühel ja “120” teisel küljel.
English: Nateglinide should be used with caution in patients with moderate hepatic impairment.
Estonian: Maksakahjustus Mõõduka maksakahjustusega patsientidel tuleb nategliniidi kasutamisel olla ettevaatlik.
English: Your ability to concentrate or react may be reduced if you have low blood sugar (hypoglycaemia).
Estonian: Madala veresuhkru korral (hüpoglükeemia) võib kontsentratsiooni- või reaktsioonivõime langeda.
English: 120 mg yellow, ovaloid tablets with “STARLIX” marked on one side and “120” on the other.
Estonian: 120 mg tabletid on kollast värvi, ovaalse kujuga, tähistusega “STARLIX” ühel ja “120” teisel küljel.
English: 180 mg red, ovaloid tablets with “STARLIX” marked on one side and “180” on the other.
Estonian: 180 mg tabletid on punast värvi, ovaalse kujuga, tähistusega “STARLIX” ühel ja “180” teisel küljel.
English: 60 mg pink, round, bevelled-edge tablets with “STARLIX” marked on one side and “60” on the other.
Estonian: 60 mg tabletid on roosat värvi, ümara kuju ja kaldservaga, tähistusega “STARLIX” ühel ja “60” teisel küljel.
English: Other events
Estonian: Muud kõrvaltoimed
English: What Starlix looks like and contents of the pack Starlix 60 mg film-coated tablets are pink, round tablets with “STARLIX” marked on one side and “60” on the other.
Estonian: Starlix 60 mg õhukese polümeerikattega tabletid on roosat värvi, ümmargused, tähistusega “STARLIX” ühel ja “60” teisel küljel.
English: Talk to your doctor before taking Starlix - if you know that you have a liver problem.
Estonian: Enne Starlix'i võtmist pidage nõu oma arstiga.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Ovaleap on 27 September 2013.
Estonian: Euroopa Komisjon andis Ovaleapi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 27. septembril 2013.
English: What measures are being taken to ensure the safe and effective use of Ovaleap?
Estonian: Mis meetmeid võetakse, et tagada Ovaleapi ohutu ja efektiivne kasutamine?
English: The full EPAR for Ovaleap can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Ovaleapi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: A risk management plan has been developed to ensure that Ovaleap is used as safely as possible.
Estonian: Töötati välja riskijuhtimisstrateegia, et tagada Ovaleapi võimalikult ohutu kasutamine.
English: After the first injection, the patient or their partner may give the injections themselves, if they are well motivated, have been trained and have access to expert advice.
Estonian: Pärast esimest süsti võivad patsient või tema partner ise ravimit süstida, kui nad seda soovivad ja on saanud vastava väljaõppe ning neil on võimalik asjatundjalt nõu küsida.
English: This is called ‘ovarian hyperstimulation syndrome'.
Estonian: Seda nimetatakse munasarjade hüperstimulatsiooni sündroomiks.
English: The main measure of effectiveness was the number of oocytes (immature eggs) collected.
Estonian: Uuringu efektiivsuse põhinäitaja oli kogutud ovotsüütide (küpsemata munarakkude) arv.
English: • men who have hypogonadotrophic hypogonadism (a rare hormone deficiency disease).
Estonian: • mehed, kellel on hüpogonadotroopne hüpogonadism (hormoonpuudulikkusest tingitud haruldane haigus).
English: Ovaleap follitropin alfa
Estonian: Ovaleap alfafollitropiin
English: Why is Ovaleap approved?
Estonian: Miks Ovaleap heaks kiideti?
English: What is Ovaleap and what is it used for?
Estonian: Mis on Ovaleap ja milleks seda kasutatakse?
English: Previously, the FSH used in medicines was extracted from urine.
Estonian: Varem eraldati ravimites kasutatav FSH uriinist.
English: Other information about Ovaleap
Estonian: Muu teave Ovaleapi kohta
English: The most common side effects with Ovaleap (which may affect more than 1 in 10 people) are reactions at the injection site (pain, redness, bruising, swelling or irritation).
Estonian: Ovaleapi kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on süstekoha reaktsioon (valu, punetus, verevalum, turse ja ärritus).
English: This means that Ovaleap is similar to a biological medicine (the ‘reference medicine') that is already authorised in the European Union (EU) and that Ovaleap and the reference medicine contain the same active substance.
Estonian: See tähenda, et Ovaleap on sarnane bioloogilise ravimiga (võrdlusravimiga), millel juba on Euroopa Liidus müügiluba ning mis sisaldab sama toimeainet.
English: The dose of Ovaleap and how often it is given depend on why it is being used and on the patient's response to treatment.
Estonian: Ovaleapi annus ja manustamissagedus sõltuvad sellest, milleks ravimit kasutatakse, ja patsiendi ravivastusest.
English: Ovaleap has been compared with GONAL-f in one main study involving 299 women undergoing fertility treatment.
Estonian: Ovaleapi võrreldi ravimiga GONAL-f ühes põhiuuringus 299 naisel, kes said viljatusravi.
English: Therefore, the CHMP's view was that, as for GONAL-f, Ovaleap's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Seetõttu otsustas inimravimite komitee, et nagu ka ravimi GONAL-f korral, on Ovaleapi kasulikkus suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Ovaleap, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Strateegiast lähtudes lisati ravimi omaduste kokkuvõttesse ja pakendi infolehele Ovaleapi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: It must not be used when it would not be possible for the patient to have an effective response, such as in patients whose ovaries or testicles do not work or in women who should not get pregnant for medical reasons.
Estonian: Ravimit ei tohi kasutada ka juhul, kui ravivastuse tekkimine patsiendil on võimatu, näiteks patsiendid, kellel puudub munasarjade või munandite talitlus, või naised, kes ei tohi tervislikel põhjustel rasestuda.
English: What are the risks associated with Ovaleap?
Estonian: Mis riskid Ovaleapiga kaasnevad?
English: This is a summary of the European public assessment report (EPAR) for Ovaleap.
Estonian: See on ravimi Ovaleap Euroopa avaliku hindamisaruande kokkuvõte.
English: In women, ovarian cysts (sacs of fluid within the ovaries) and headache are also seen in more than 1 patient in 10.
Estonian: Naistel on munasarjatsüste (vedelikukogumid munasarjas) ja peavalu esinenud enam kui 1 patsiendil 10st.
English: It is not intended to provide practical advice on how to use Ovaleap.
Estonian: Hindamisaruandes ei anta Ovaleapi kasutamise praktilisi nõuandeid.
English: It is used to treat the following groups:
Estonian: Ovaleapi kasutatakse järgmistel patsiendirühmadel:
English: The follitropin alfa in Ovaleap, as well as in the reference product GONAL-f, is produced by a method known as ‘recombinant DNA technology': it is made by cells into which a gene (DNA) has been introduced that makes them able to produce human FSH.
Estonian: Ovaleapis ja võrdlusravimis GONAL-f sisalduvat alfafollitropiini valmistatakse rekombinant-DNA-tehnoloogia abil: seda toodab rakk, millele on lisatud inimese FSH teket võimaldav geen (DNA).
English: The average number of oocytes collected was 12.2 in the Ovaleap group, compared with 12.0 in the GONAL-f group.
Estonian: Uuring näitas, et Ovaleap on sarnane võrdlusravimiga GONAL-f. Keskmine kogutud ovotsüütide arv oli Ovaleapi rühmas 12,2 ja ravimi GONAL-f rühmas 12,0.
English: Ovaleap is a medicine that contains the active substance follitropin alfa.
Estonian: Ovaleap on ravim, mis sisaldab toimeainena alfafollitropiini.
English: Ovaleap must not be used in people who are hypersensitive (allergic) to follitropin alfa, FSH, or any of the other ingredients.
Estonian: Ovaleapi ei tohi kasutada inimesed, kes on alfafollitropiini, FSH või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: It must not be used in patients with tumours of the pituitary gland or hypothalamus, or cancer of the breast, womb or ovary.
Estonian: Ovaleapi ei tohi kasutada patsiendid, kellel on hüpofüüsi või hüpotalamuse kasvaja või munasarja-, emaka- või rinnanäärmekasvaja.
English: The reference medicine for Ovaleap is GONAL-f. For more information on biosimilar medicines, see the question-and-answer document here.
Estonian: Ovaleapi võrdlusravim on GONAL-f. Lisateave bioloogiliselt sarnaste ravimite kohta on teabedokumendis siin.
English: For practical information about using Ovaleap, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Ovaleapi kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: For the full list of all side effects reported with Ovaleap, see the package leaflet.
Estonian: Ovaleapi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Ovaleap is given by injection under the skin once a day.
Estonian: Ovaleapi manustatakse nahaaluse süstina üks kord ööpäevas.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that Ovaleap has been shown to have a comparable quality, safety and efficacy profile to GONAL-f.
Estonian: Inimravimite komitee järeldas, et Ovaleapi kvaliteet, ohutus ja efektiivsus on sarnased võrdlusravimi GONAL-f vastavate näitajatega.
English: The medicine can only be obtained with a prescription and treatment should be started under the supervision of a doctor who has experience in the treatment of fertility problems.
Estonian: Ravi Ovaleapiga peab toimuma viljakusprobleemide ravis kogenud arsti järelevalve all.
English: In women, Ovaleap must not be used when there is enlargement or a cyst of the ovary caused by something other than polycystic ovarian disease, or when there is unexplained bleeding from the vagina.
Estonian: Naised ei tohi Ovaleapi kasutada munasarjade suurenemise või sellise tsüsti korral, mis ei ole tingitud munasarjade polütsüstilisest haigusest, ega teadmata põhjusega tupeverejooksu korral.
English: • women with severe deficiency (very low levels) of luteinising hormone (LH) and follicle stimulating hormone (FSH).
Estonian: • naised, kellel on luteiniseeriva hormooni (lutropiin, LH) ja folliikuleid stimuleeriva hormooni (FSH)
English: How is Ovaleap used?
Estonian: Kuidas Ovaleapi kasutatakse?
English: Ovaleap is given to stimulate the ovaries to produce more than one egg at a time;
Estonian: Ovaleapi manustatakse munasarjade stimuleerimiseks, et neis tekiks korraga mitu munarakku;
English: For more information about treatment with Ovaleap, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Ovaleapiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Ovaleap is given together with a medicine containing LH to stimulate the eggs to mature in the ovaries;
Estonian: Ovaleapi manustatakse koos luteiniseerivat hormooni sisaldava ravimiga, et stimuleerida munarakkude küpsemist munasarjades;
English: Ovaleap is used together with human chorionic gonadotrophin (hCG) to stimulate sperm production.
Estonian: Ovaleapi kasutatakse sperma tekke stimuleerimiseks koos inimese kooriongonadotropiiniga (hCG).
English: Ovaleap is a ‘biosimilar' medicine.
Estonian: Ovaleap on bioloogiliselt sarnane ravim.
English: • women who are undergoing assisted reproductive techniques (fertility treatment) such as in-vitro fertilisation.
Estonian: • viljatusravi saavad naised (tehisviljastamine, näiteks katseklaasis viljastamine).
English: How does Ovaleap work?
Estonian: Kuidas Ovaleap toimib?
English: What benefits of Ovaleap have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Ovaleapi kasulikkus?
English: The active substance in Ovaleap, follitropin alfa, is a copy of the natural hormone FSH.
Estonian: Ovaleapi toimeaine alfafollitropiin on loodusliku folliikuleid stimuleeriva hormooni (FSH) tehisvariant.
English: • women who do not produce eggs and do not respond to treatment with clomiphene citrate
Estonian: • naised, kellel ei teki munarakke ja kelle ravi klomifeentsitraadiga (samuti ovulatsiooni stimuleeriv ravim) ei ole andnud tulemusi;